Author

Max Harris

University of California, San Francisco

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:perturbation response prediction· 1 Approach:statistical model· 1

Frequent Co-Authors

Benjamin J. HuangiD· 2 shared Kevin ShannoniD· 2 shared Aishwarya C. Ballapuram· 1 shared Alexa Rane Batingana· 1 shared Anica M. WandleriD· 1 shared Benjamin F. CravattiD· 1 shared Boer Xie· 1 shared Camille J. Leung· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Benjamin J. HuangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling

Benjamin J. Huang, Jeevitha D’Souza, Alexa Rane Batingana, Max Harris, Xinyue Wang, Eugene Hwang, Anica M. Wandler, Michael R. Burgess, Qing Li, Soheil Meshinchi, Gideon E. Bollag, Kevin Shannon

This study shows that AML relapse after BET inhibitor or chemotherapy involves Myc-Ras transcriptional changes, highlighting transcriptional plasticity in relapsed leukemias.

bioRxiv · Nov 13, 2025 · PreprintCancer Biology

In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer

Matthew Decker, Benjamin J. Huang, Timothy B. Ware, Christopher D. Boone, Michelle Tang, Julia Ybarra, Matthew J. Sale, Rony A. Francois, Aishwarya C. Ballapuram, Katrine A. Taran, Esteban Tarazona-Guzman, Pan-Yu Chen, Marcos Armendariz, Camille J. Leung, Max Harris, , Kevin Shannon

This study validates the palmitoylation cycle as a therapeutic target in NRAS-mutant cancers by showing that inhibiting ABHD17 reduces tumor growth and synergizes with MEK inhibitors.

bioRxiv · Mar 20, 2025 · PreprintCancer Biology